MPO and colitis: Oral administration of OA in a mice model of colitis significantly inhibited colon shortening and myeloperoxidase activity, displayed potent anti-inflammatory properties by reducing the activation of TNF-α, IL-1β, IL-17, NF-κB, and MAPK, and increasing the expression of IL-10.